Affinity selection and sequence-activity relationships of HIV-1 membrane fusion inhibitors directed at the drug-resistant variants
. 2 Enfuvirtide is effective even against the clinical strains that are resistant to multiple drug classes such as reverse transcriptase inhibitors and protease inhibitors used in highly active antiretroviral therapy (HAART). However, the emergence of enfuvirtide-resistant strains has been reported in patients receiving long-term enfuvirtide treatment. 3, 4 The primary evolution of enfuvirtide resistance occurs on gp41 N-HR, which attenuates the binding affinity with enfuvirtide, resulting in decreased drug susceptibility. [3] [4] [5] The major primary mutations are V38A and N43D in the Leu33-Leu45 region of N-HR. These mutations subsequently lead to a secondary mutation appearing in C-HR, which can compensate the binding affinity between viral N-HR and C-HR for efficient gp41 folding. 6 For example, N126K and S138A mutations have been reported to enhance the resistance induced by enfuvirtide and another inhibitory C-HR peptide, C34. These complementary mutations, which occur at the face-to-face positions of N-HR and C-HR verified by crystallographic studies, [7] [8] [9] can restore the critical step required for viral infection into the target cells and eliminate the inhibitory effect of exogenous enfuvirtide. Recently, several novel fusion inhibitors such as tifuvirtide (T-1249) 10 and sifuvirtide, Initially, C-HR peptide libraries with a variety of canonical amino acid substitutions at the positions to be optimized (Ser138 and Gln141) were prepared by a split-pool method. After the construction of the C-terminal sequence using a standard Fmoc-based solid-phase peptide synthesis approach, the resin was split into fractions at position 138 or 141, where proteinogenic amino acids except for cysteine were coupled in parallel. The 19 fractions were combined again and the Nterminal sequence was constructed in one portion. All the protected peptide resins were treated with a cocktail of deprotection reagents, and the crude peptides were purified by reversed-phase HPLC to afford the expected peptides.
Separately, in order to rationalize the selection process by affinity-based technology and to investigate the sequence-activity relationship, all C-HR peptides with a single substitution were wild-type HIV-1 NL4-3 or the variants with enfuvirtide-resistant mutations were evaluated using the MAGI assay. Thermal stabilities of the potential six-helical bundles consisting of N-HR and C-HR peptides were evaluated by measuring the melting temperature (T m ) using the molar ellipticity value at 222 nm in circular dichroic (CD) spectra of N36/SC35EK or N54/T-20EK mixture ( Figure S1 ).
The AS-MS protocol was optimized using SC35EK derivatives (Table 1) . A pool of SC35EK S138X was incubated with a wild-type N-HR peptide, N36 (10 µM) with an N-terminal His 6 -tag, in HEPES buffer (pH 7.4). The potential six-helical bundles of N36-SC35EK S138X were captured by Ni-NTA agarose resin and were subsequently eluted with 50% AcOH (Figure 2a ). The captured components were separated and characterized by LC-MS analysis, except that the peptides with Leu and Ile were observed as overlapping peaks of the same mass-to-charge ratio ( Figure 2b ).
The recovery rate in affinity selection for relative binding ability to N36 was calculated from the detected signal of [M+3H] 3+ and [M+4H] 4+ ions of each C-HR peptide by the LC-MS analysis of captured peptides. Under the high concentration conditions (10 µM each of SC35EK S138X ), several potent peptides including a resistant variant-derived S138A peptide were captured in high recovery rates, while slightly less potent peptides such as SC35EK S138F and SC35EK S138Y were not detected.
In contrast, when the total concentration of the mixture was nearly equal to the N36 concentration (0.6 µM each of SC35EK S138X ), there was no discernible difference in the recovery rates of each peptide. The compound with the least potent anti-HIV activity in the series, SC35EK S138R , was recovered under this equimolar concentration conditions. This recovery suggested that the method is not effective under lower concentration conditions of C-HR peptides. A condition using 1 µM each of SC35EK S138X (total 19 µM of the mixture) for affinity selection was selected for further experiments, in which the recovery rate was found to positively correlate with the stability of the six-helical bundle (Figure 3a) . Although an ideal linear correlation was not observed between the logarithmic EC 50 of anti-HIV activity and the recovery rate (Figure 3b) , the peptides, which were captured in relatively high yields by affinity selection, exhibited highly potent anti-HIV activity.
The optimized condition was applied for the selection of T-20EK S138X derivatives ( Table 2 ). The anti-HIV activity of T-20EK S138X was found to be dependent on the amino acid type at position 138.
Substitution with aliphatic side-chain amino acids such as Ala, Ile, Leu, Met and Val, displayed highly potent anti-HIV activity, although significant stabilization of the N54-T-20EK S138X complexes was not observed. Gly-and Thr-substitutions were also observed to increase potency. In contrast, hydrophilic, charged and aromatic amino acid substitutions at position 138 reduced binding with N54. In our previous study, it was demonstrated that higher affinity with the N-HR sequence and more potent anti-HIV activity of C34 S138A and T-20 S138A were due to the dominant contribution of larger desolvation free energy of the hydrophobic side-chain. 8 The structure-activity relationship of T-20EK S138X can be partially rationalized by the similar hydrophobic/hydrophilic properties of the side-chain. The recovery rates of T-20EK S138X in affinity selection showed good correlations with both anti-HIV activity and with thermal stability of the complexes (Figures 3c and   3d ). The peptides captured with more than 9% recovery yields exhibited sub-nanomolar potency along with T m values >75°C.
The anti-HIV activities of the series of peptides against recombinant viruses with either the enfuvirtide-resistant V38A or N43D mutation in N-HR were evaluated. The results of representative C-HR peptides, which were obtained by a single nucleotide mutation of HIV-1 NL4-3 , are shown in Table 3 and Figure S2 . From Ser138 encoded by the TCG codon in wild-type NL4-3, Ala (GCG), Pro (CCG), Thr (ACG), Leu (TTG) and Trp (TGG) are possible mutations; the other mutations are silent (TCA, TCT, TCC) or a stop codon (TAG). The S138A substitution in both SC35EK and T-20EK enhanced the thermal stability of the N-HR/C-HR complex, indicating that this is a favorable mutation in terms of gp41 folding of the resistant virus. 3, 4 These peptides by mutant-directed design restored and enhanced the anti-HIV activity against enfuvirtide-resistant variants. The S138L peptide was also effective against both V38A and N43D strains; however, no emergence of a clinical variant having this mutation has been reported. Of interest, resistant viruses are unlikely to necessarily use the best C-HR substitution to complement the gp41 folding, presumably due to the low replication kinetics. These results indicate that the mutations observed in clinical variants can direct the position to be optimized for inhibitor design but not the most appropriate amino acids. In practice, several other substitutions by Ile and Met, which are irrelevant to single nucleotide mutations from the wild-type, also provided potent anti-HIV activity against the resistant strains (Table S4 ). In contrast, substitution with Pro or Trp for both peptides significantly decreased the activity, which is consistent with the results against the wild-type virus. Lower stabilities of the six-helical bundle structure consisting of S138T peptides and mutant N-HR peptides were shown, but SC35EK S138T was slightly more potent against both resistant viruses compared with the parent peptide.
Using His-tagged N36 or N54 peptides with the V38A or N43D mutation, affinity selection experiments were performed for SC35EK S138X and T-20EK S138X including 19 components (Table 3 and Table S4 ). Eight SC35EK derivatives captured in significantly high yields all showed potent anti-HIV activity against the V38A mutant. Moderate recovery yields of SC35EK S138E and SC35EK S138Y could result from potential false positive and negative results of the selection, respectively. Although T-20EK derivatives showed lower susceptibility against the V38A mutant in the MAGI assay, an association between the high recovery rate and more potent anti-HIV activity was observed such as S138A, S138I, S138L and S138M derivatives (Figures S3). Similar correlations were also obtained against N43D variants. SC35EK S138X and T-20EK S138X components, which exhibited subnanomolar potent bioactivity, were recovered in moderate to good yields.
Overall favorable amino acids for position 138 of the wild-type were useful for designing C-HR peptides against V38A and N43D variants and vice versa, suggesting that the essential binding mode around this position is conserved even after acquiring the enfuvirtide resistance.
The structure-activity relationships of Q141 modifications were also investigated ( T m values of Q141P derivatives suggested that the sole proline residue precluded the formation of a bioactive α-helix structure. On the other hand, high potency of the other peptides independent of any other acyclic amino acid substitution at position 141 may be attributable to the lower importance of the Q141 position for the binding affinity between N-HR and C-HR than the S138 position. Among these, Q141I, Q141L and Q141M peptides formed slightly more stable complexes with N36 or N54 and were captured at a relatively higher recovery rate by affinity selection. These substitutions were found to contribute to subnanomolar anti-HIV activity of T-20EK derivatives;
however, these peptides were less valid for SC35EK derivatives.
For both S138 and Q141 substitutions, it does not seem possible to distinguish between variations of a few nM in anti-HIV activity by affinity selection. This is particularly the case for the selections regarding less effective residues such as Q141 of SC35EK. In contrast, over a larger range of more than 2 orders of magnitude of affinity variations of T-20EK derivatives, the selection procedure correlated reasonably well with the anti-HIV activity and six-helix bundle stability. In both sequences, highly potent anti-HIV activity peptides were captured in good to high yields.
Conclusions
In conclusion, we have presented an affinity selection-mass spectrometry method to explore novel HIV-1 fusion inhibitors. Predicated on previous findings that the introduction of α-helix-inducible X-EE-XX-KK motifs into inhibitory C-HR peptides should improve peptide solubility in aqueous buffers and disclose the interactive surface to be optimized, a pool of SC35EK and T-20EK derivatives with a single modification at two interactive positions were screened using N-HR peptides corresponding to wild-type and enfuvirtide-resistant strains. Through the screening of position 138 on C-HR, it was demonstrated that potent anti-HIV peptides could be obtained by substitutions with resistance-related and resistance-independent amino acids. Since a wide variety of synthetic peptides with any unnatural amino acids or peptidomimetics could be employed as candidate components, the system should be applicable to screening for inhibitory α-helix peptides of coiled-coil interactions. The structure-activity relationships of C-HR peptides presented herein this process is considered to reproduce the evolutionary process of HIV-1 gp41 to select the appropriate folding partners in the presence of fusion inhibitors, the sequence-activity relationships could facilitate understanding of the underlying mechanisms of enfuvirtide resistance. (a, b) SC35EK S138X ; (c, d) T-20EK S138X . R 2 values for the correlation of SC35EK S138X data were calculated without using the data points of S138R/K/P/D mutants (n = 15). ions by LC-MS analysis. b EC 50 was determined as the concentration that blocked HIV-1 NL4-3 replication by 50% in the MAGI assay. To improve the replication kinetics, the D36G mutation, observed in the majority of HIV-1 strains, was introduced into the NL4-3 background used in this study.
c T m values were defined by the midpoint of the thermal unfolding transition state measured by monitoring the molar ellipticity at 222 nm of N36/SC35EK S138X mixture.
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